Nuvation Bio Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Nuvation Bio Inc. (NUVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $2.59 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-03-02
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $3.38, a 16.54% decline year-over-year.
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.05.
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $2.59, a 16.14% increase from fiscal 2024.
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $2.23, a 13.23% decline from fiscal 2023.
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $2.57, a 14.33% decline from fiscal 2022.
- Nuvation Bio Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $3.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.59 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $2.23 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $2.93 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $2.80 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $3.38 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $2.57 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $3.87 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $3.87 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $4.05 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $3.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |